Business Context and Reporting Period
This Form 8-K is filed by Angion Biomedica Corp. (not Elicio Therapeutics, Inc., as indicated in the metadata) on August 15, 2022. The filing serves to announce the Company's financial results for the fiscal quarter ended June 30, 2022. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol ANGN.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing explicitly states that the detailed financial results are contained in a press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the text of this 8-K.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the issuance of a press release containing the Q2 2022 results.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risks, or contingencies. It notes that the information furnished under Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the discrepancy between the metadata company name ("Elicio Therapeutics, Inc.") and the actual registrant ("Angion Biomedica Corp.").
- Locate and review Exhibit 99.1 (the press release) to obtain actual revenue, net income, and cash flow figures for the quarter ended June 30, 2022.
- Confirm the Company's status as an emerging growth company (indicated as "Yes" in the filing).
- Review the full press release for any material changes in clinical trial progress or regulatory status not detailed in this summary.